EMA Application withdrawn: Neocepri (folic acid) — Endocyte Europe, B.V.

View source ↗

Summary

The EMA withdrew the application for Neocepri (folic acid) by Endocyte Europe, B.V., with therapeutic areas including ovarian neoplasms and radionuclide imaging…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms
• Radionuclide Imaging Is Diagnostic Modality Rather Than Disease Included As Therapeutic Area But Not Disease If Strictly Disease Terms Are Required List Only Ovarian Neoplasms

Drugs mentioned

• Neocepri (folic acid)

Snippet

Status: Application withdrawn. Therapeutic area: Ovarian Neoplasms;Radionuclide Imaging. MAH: Endocyte Europe, B.V.. Decision date: 21/03/2014